Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323726 | 0.90 | POLB (0.44) | POLBALDH1A1PTGS2CYP3A4CYP2C19 | |
| SCHEMBL13323727 | 0.85 | POLB (0.36) | POLBALDH1A1PTGS2HCRTR1HCRTR2 | |
| SCHEMBL13323570 | 0.79 | GCK (0.38) | PTGS2 | |
| SCHEMBL2656981 | 0.76 | POLB (0.43) | POLBALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13323938 | 0.70 | ALDH1A1 (0.43) | POLBALDH1A1CYP3A4CYP2C19NPC1 | |
| SCHEMBL2656464 | 0.66 | POLB (0.52) | POLBALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13323548 | 0.64 | ALDH1A1 (0.40) | POLBALDH1A1PTGS2CYP3A4CYP2C19 | |
| SCHEMBL2656118 | 0.64 | GCK (0.56) | POLBALDH1A1PTGS2NPC1RAB9A | |
| SCHEMBL24065714 | 0.62 | PTGS2 (0.54) | ALDH1A1PTGS2AKR1C3SMN1; SMN2 | |
| SCHEMBL13323747 | 0.61 | ALDH1A1 (0.42) | POLBALDH1A1CYP3A4CYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144772-A1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144772-A1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | GCK, GCKR, GALK1 | POLB 1940/4885ALDH1A1 924/4885PTGS2 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.